NanoViricides, Inc. is a development stage, publicly traded, fully reporting company (symbol: NNVC). 
It has developed a unique nanomedicine-based approach to develop novel anti-viral agents.
A NanoViricide™ is a specially designed, flexible, nanomaterial that may contain an
encapsulated active pharmaceutical ingredient and is specifically targeted to a specific
type of virus, like a guided missile. NanoViricide drugs are designed to block and
dismantle the virus particles before they can infect a cell, thereby controlling viremia.



http://www.nanoviricides.com/nnvc-tem.pdf

Drugs in Development

Pre-Clinical Studies:

Drugs Currently Nearing completion of Animal Studies:

1. HerpeCide for Herpes Simplex Virus, HSV-1 and HSV-2
2. HivCide for treatment of HIV and AIDS
3. EkcCide for treatment of Epidemic Keratoconjunctivitis (Viral Pink Eye)
4. RabiCide for Rabies

Drugs Currenly in Pre-cinical testing:

1. AviFluCide for Bird Flu H5N1
2. FluCide I for Swine Flu H1N1 and all other influenzas
3. Epidemic Keratoconjunctivitis antiviral (EKC)
4. HSV-1 and HSV-2 antiviral
5. EbolaCide for Ebola
6. DengueCide for Dengue
   

Future Studies Currently Planned by NNVC:

Marburg
Rift Valley Fever
West Nile Fever
Junin virus
Machupo virus
Lassa Fever
Hanta Virus
CMV Eye
Hepatitis B & C
Chukungunya Fever

Delivery Methods for a nanoviricide:

• Injectables
• Bronchial Sprays
• Nasal Sprays (Nose Drops)
• Ocular (Eye Drops)
• Oral for special circumstances
• Skin Patches
  

 

NNVC web site:
http://www.nanoviricides.com/

Investor Relations Contact:

NanoViricides, Inc.
Amanda Schuon
310-550-7200
info@nanoviricides.com


NNVC SI message board:
http://www.siliconinvestor.com/subject.aspx?subjectid=55797

NANOVIRICIDES, INC Quarterly Report 9-30-2009
http://sec.gov/Archives/edgar/data/1379006/000114036109027116/form10q.htm

Share Structure as of November 23, 2009 confirmed with TA

• O/S: 131,774,554 
• Authorized: 300 million
  

Transfer Agent:
  www.corporatestock.com/

Allexcel Patents

1. (WO 2009/011702) SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS
The invention provides amphiphilic biocompatible copolymers which have a hydrophilic backbone and pendant hydrophobic groups. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors within which anticancer drugs may be solubilized. The polymers optionally feature attached antibodies, receptor ligands, and other targeting moieties which mediate adherence of the drug-carrying aggregates to targeted cancer cells.

2. (WO 2008/091246) SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS
There are provided amphiphilic biodegradable copolymers comprising a hydrophilic backbone with pendant aliphatic groups as the hydrophobic component. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors that are capable of solubilizing insoluble organic compounds and disrupting viral coat proteins. The polymers optionally feature reactive functional groups that provide attachment points for antibodies, ligands, and other targeting moieties which mediate adherence of the aggregate to a viral target.

3. (WO 2007/084126) SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS
There are provided amphiphilic biodegradable copolymers comprising a hydrophilic backbone with pendant aliphatic groups as the hydrophobic component. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors that are capable of solubilizing insoluble organic compounds such as drugs, vitamins, dyes, and imaging agents. The polymers optionally feature reactive functional groups that provide attachment points for antibodies, ligands, and other targeting moieties useful for the targeted delivery of drugs and imaging agents.

NNVC News:

NanoViricides, Inc. Anti-Herpes Drug Candidate Reduces Viral Load by 99.99%

finance.yahoo.com/news/NanoViricides-Inc-AntiHerpes-bw-639720699.html

NanoViricides, Inc. Signs Agreement with a Major Pharma

Material Transfer Agreement is First Step Towards Licensing Agreement

Monday March 2, 2009, 7:00 am EST

finance.yahoo.com/news/NanoViricides-Inc-Signs-bw-14508185.html

NanoViricides, Inc. Reports that HIVCide-I Was Significantly Superior to the Current Anti-HIV Three Drug Cocktail Standard
The Novel Mechanism of Action of HIVCide-I Defines a New Class of Anti-HIV Drugs -Monday August 11, 7:00 am ET

http://www.nanotechwire.com/news.asp?nid=6461

NanoViricides, Inc. Signs Rabies Agreement with CDC for Expanded Research
Study to Evaluate Usage Strategy for further Development towards Drug Approval -Monday August 4, 7:00 am ET

http://www.nanotechwire.com/news.asp?nid=6414

NanoViricide's EKC Eye Drug Candidate Stopped Clinical Conjunctivitis Pathology
Statistical Data Analysis Revealed Excellent Efficacy Using Clinical Scores in Animal Study; Confirmed Photographic Findings

http://www.medicalnewstoday.com/articles/115204.php

NanoViricides in Discussions with Pharma about EKC Eye Drug Candidate
Non-Disclosure Agreements Signed; Meetings Scheduled, says Company
http://www.drugs.com/clinical_trials/nanoviricides-discussions-pharma-ekc-eye-candidate-4445.html

NanoViricides' EKC Eye Drug Demonstrates Significant Therapeutic Efficacy in Initial Animal Trials
First Treatment Success against a Non-Enveloped Virus
www.reuters.com/article/pressRelease/idUS103906+19-May-2008+BW20080519

Anti-HIV NanoViricide Drug Candidate Demonstrates Significant Therapeutic Efficacy in Animal Trials
Positive Initial Results Pave the Way for Definitive Follow-Up Studies
nanotechwire.com/news.asp

Nanoviricides Found Highly Effective against Ebola by USAMRIID
http://news.moneycentral.msn.com/ticker/article.aspx?symbol=US:NNVC&feed=BW&date=20080219&id=8205799

WallStreetWeek.com Interview with Eugene Seymour, MD, MPH Chief Executive Officer NNVC
http://www.wallstreetreporter.com/page.php?page=featured&tab=2&id=27515

Link to transcripted highlights of the WallStreetWeek.com interview
http://investorshub.advfn.com/boards/read_msg.asp?message_id=24596813

New Images Show Virus Dismantled by Broad-Spectrum NanoViricides
Electron Micrographs Confirm Virus Destruction
Thursday May 31, 5:45 pm ET
findarticles.com/p/articles/mi_m0EIN/is_2007_May_31/ai_n19376822

NanoViricides Drug Effectiveness Confirmed against Rabies and Influenzas
http://www.nanotechwire.com/news.asp?nid=5251&ntid=&pg=40

Nanoviricides, Inc. and U.S. Defense Dept. Agency
Sign Joint Research and Development Agreement to Fight Dengue Fever
Dengue Fever Treatment R&D Comes as Disease Surges in Hot-climate Regions
Monday April 9, 7:05 am ET
http://findarticles.com/p/articles/mi_m0EIN/is_2007_April_9/ai_n18791897

NanoViricides, Inc. Achieves Broad Success in Initial FluCide-I™ Anti-Influenza Studies;
Company Says That Nanoviricides™ is Now a Proven Platform To Attack Bird Flu
http://www.findarticles.com/p/articles/mi_m0EIN/is_2006_March_20/ai_n16109928